Revance Therapeutics Inc’s recently made public that its CFO Schilke Tobin unloaded Company’s shares for reported $47204.0 on Mar 18 ’24. In the deal valued at $5.04 per share,9,361 shares were sold. As a result of this transaction, Schilke Tobin now holds 192,666 shares worth roughly $0.85 million.
Then, Sjuts Dustin S sold 9,211 shares, generating $46,446 in total proceeds. Upon selling the shares at $5.04, the President now owns 167,550 shares.
Before that, Moxie Dwight sold 8,125 shares. Revance Therapeutics Inc shares valued at $40,971 were divested by the CLO & GC at a price of $5.04 per share. As a result of the transaction, Moxie Dwight now holds 137,815 shares, worth roughly $0.61 million.
Mizuho downgraded its Revance Therapeutics Inc [RVNC] rating to a Neutral from a a Buy in a research note published on January 29, 2024; the price target was decreased to $9 from $16. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in early January from “a Buy” to “a Neutral”. Exane BNP Paribas also remained covering RVNC and has increased its forecast on August 16, 2023 with a “Neutral” recommendation from previously “an Underperform” rating. Morgan Stanley started covering the stock on October 11, 2022. It rated RVNC as “an Equal-weight”.
Price Performance Review of RVNC
On Friday, Revance Therapeutics Inc [NASDAQ:RVNC] saw its stock unchanged to $4.41. Over the last five days, the stock has lost -10.37%. Revance Therapeutics Inc shares have fallen nearly -49.83% since the year began. Nevertheless, the stocks have fallen -86.80% over the past one year. While a 52-week high of $37.98 was reached on 01/02/24, a 52-week low of $4.36 was recorded on 04/05/24. SMA at 50 days reached $5.49, while 200 days put it at $11.60. A total of 1.26 million shares were traded, compared to the trading of 1.33 million shares in the previous session.
Levels Of Support And Resistance For RVNC Stock
The 24-hour chart illustrates a support level at 4.34, which if violated will result in even more drops to 4.26. On the upside, there is a resistance level at 4.48. A further resistance level may holdings at 4.54. The Relative Strength Index (RSI) on the 14-day chart is 34.88, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.32, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.66%. Stochastics %K at 7.53% indicates the stock is a buying.
How much short interest is there in Revance Therapeutics Inc?
A steep rise in short interest was recorded in Revance Therapeutics Inc stocks on Mar 15, 2024, dropping by -1.47 million shares to a total of 10.87 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 12.34 million shares. There was a decline of -13.52%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 11.97% of the overall stock float, the days-to-cover ratio (short ratio) fell to 4.95.
The most recent change occurred on September 22, 2022 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $33 price target.
